Update on Thromboembolic Events After Vaccination Against COVID-19

Area of Science:

• Immunology
• Vaccinology
• Thrombosis Research

Background:

• COVID-19 vaccination has raised concerns regarding thromboembolic events, particularly with adenoviral vector vaccines.
• Thromboembolic complications, including VITT, ATE, and VTE, are rare but documented post-vaccination.

Purpose of the Study:

• To review the occurrence and characteristics of thromboembolic and renal complications following COVID-19 vaccination.
• To compare the thrombotic risk associated with different vaccine platforms.
• To emphasize current management strategies and the overall benefit-risk profile of COVID-19 vaccines.

Main Methods:

• Literature review of studies on COVID-19 vaccines and thromboembolic events.
• Analysis of reported cases of VITT, VTE, ATE, and renal complications.
• Comparative analysis of thrombotic risk between adenoviral vector and mRNA vaccines.

Main Results:

• Thromboembolic events (VTE, ATE, VITT) and rare renal complications are uncommon following COVID-19 vaccination.
• Risk factors include age, sex, vaccine type, and comorbidities.
• mRNA vaccines demonstrate a significantly lower risk of serious thrombotic events compared to adenoviral vector vaccines.

Conclusions:

• Despite rare thrombotic complications, COVID-19 vaccines are crucial for preventing severe disease and mortality.
• Individualized risk assessment and prompt management are key.
• mRNA vaccines are preferred due to a lower thrombotic risk profile.